Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyret
- PDF / 123,388 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 21 Downloads / 193 Views
CORRECTION
Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid Augustus Hough 1
&
Jessica Wearden 2 & Kristen de Almeida 3 & Stephanie Kaiser 1
Published online: 28 September 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Correction to: Current Cardiology Reports (2020) 22:106 https://doi.org/10.1007/s11886-020-01374-2 On page 2 of the original publication, in the section on TTR Silencers, dosing of patisiran in the APOLLO study was stated as being given every 3 months; this is inaccurate as patisiran was dosed every 3 weeks in the APOLLO study. The corrected sentence is presented below: “Patisiran, as an intravenous infusion every 3 weeks, also slowed functional decline versus placebo in the APOLLO study; however, in contrast to inotersen, 56% of patients had an improvement in functional outcomes from baseline [14].”
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/ 10.1007/s11886-020-01374-2 * Augustus Hough [email protected] Jessica Wearden [email protected] Kristen de Almeida [email protected] Stephanie Kaiser [email protected] 1
Clinical Pharmacy Specialist – Cardiology, West Palm Beach Veterans Affairs Medical Center, 7305 N. Military Trial, West Palm Beach, FL 33410, USA
2
PGY2 Cardiology Pharmacy Practice Resident, West Palm Beach Veterans Affairs Medical Center, West Palm Beach, FL, USA
3
Clinical Pharmacy Specialist – Cardiology, Baptist Hospital of Miami, 8900 N. Kendall Dr, Miami, FL 333176, USA
Data Loading...
